{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T20:17:29Z","timestamp":1781295449555,"version":"3.54.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T00:00:00Z","timestamp":1702684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T00:00:00Z","timestamp":1702684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s12185-023-03682-z","type":"journal-article","created":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T11:01:51Z","timestamp":1702724511000},"page":"39-49","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Contribution of post-transplantation therapy to sustained MRD negativity in multiple myeloma: a retrospective analysis"],"prefix":"10.1007","volume":"119","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0300-378X","authenticated-orcid":false,"given":"Kazuhito","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadahiro","family":"Gunji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaharu","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Uryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riku","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamiko","family":"Momoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Tanoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaichi","family":"Nishiwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,16]]},"reference":[{"key":"3682_CR1","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516\u201320.","journal-title":"Blood"},{"key":"3682_CR2","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJMoa1402888","volume":"371","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371:895\u2013905.","journal-title":"N Engl J Med"},{"key":"3682_CR3","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/S1470-2045(15)00389-7","volume":"16","author":"F Gay","year":"2015","unstructured":"Gay F, Oliva S, Petrucci MT, Conticello C, Catalano L, Corradini P, et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol. 2015;16:1617\u201329.","journal-title":"Lancet Oncol"},{"key":"3682_CR4","doi-asserted-by":"publisher","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","volume":"7","author":"M Cavo","year":"2020","unstructured":"Cavo M, Gay F, Beksac M, Pantani L, Petrucci MT, Dimopoulos MA, et al. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol. 2020;7:e456\u201368.","journal-title":"Lancet Haematol"},{"key":"3682_CR5","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311\u201320.","journal-title":"N Engl J Med"},{"key":"3682_CR6","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2204925","volume":"387","author":"PG Richardson","year":"2022","unstructured":"Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022;387:132\u201347.","journal-title":"N Engl J Med"},{"key":"3682_CR7","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","volume":"35","author":"PL McCarthy","year":"2017","unstructured":"McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35:3279\u201389.","journal-title":"J Clin Oncol"},{"key":"3682_CR8","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0140-6736(18)33003-4","volume":"393","author":"MA Dimopoulos","year":"2019","unstructured":"Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2019;393:253\u201364.","journal-title":"Lancet"},{"key":"3682_CR9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00432-021-03668-6","volume":"148","author":"S Ozaki","year":"2022","unstructured":"Ozaki S, Handa H, Koiso H, Saitoh T, Sunami K, Ishida T, et al. Propensity-score matched analysis of the efficacy of maintenance\/continuous therapy in newly diagnosed patients with multiple myeloma: a multicenter retrospective collaborative study of the Japanese Society of Myeloma. J Cancer Res Clin Oncol. 2022;148:191\u2013203.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3682_CR10","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.bbmt.2016.11.011","volume":"23","author":"RF Cornell","year":"2017","unstructured":"Cornell RF, D\u2019Souza A, Kassim AA, Costa LJ, Innis-Shelton RD, Zhang MJ, et al. Maintenance versus induction therapy choice on outcomes after autologous transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2017;23:269\u201377.","journal-title":"Biol Blood Marrow Transplant"},{"key":"3682_CR11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:309\u201322.","journal-title":"Ann Oncol"},{"key":"3682_CR12","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41409-018-0264-8","volume":"54","author":"WI Gonsalves","year":"2019","unstructured":"Gonsalves WI, Buadi FK, Ailawadhi S, Bergsagel PL, Chanan Khan AA, Dingli D, et al. Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus statement. Bone Marrow Transplant. 2019;54:353\u201367.","journal-title":"Bone Marrow Transplant"},{"key":"3682_CR13","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s12185-019-02636-8","volume":"109","author":"S Iida","year":"2019","unstructured":"Iida S, Ishida T, Murakami H, Ozaki S, Abe M, Hata H, Shimazaki C. JSH practical guidelines for hematological malignancies, 2018: III. Myeloma-1 Multiple myeloma (MM). Int J Hematol. 2019;109:509\u201338.","journal-title":"Int J Hematol"},{"key":"3682_CR14","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1182\/blood-2011-11-374249","volume":"119","author":"H Ludwig","year":"2012","unstructured":"Ludwig H, Durie BG, McCarthy P, Palumbo A, San Miguel J, Barlogie B, et al. IMWG consensus on maintenance therapy in multiple myeloma. Blood. 2012;119:3003\u201315.","journal-title":"Blood"},{"key":"3682_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41408-020-0273-x","volume":"10","author":"MA Dimopoulos","year":"2020","unstructured":"Dimopoulos MA, Jakubowiak AJ, McCarthy PL, Orlowski RZ, Attal M, Blad\u00e9 J, et al. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. Blood Cancer J. 2020;10:17.","journal-title":"Blood Cancer J"},{"key":"3682_CR16","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1200\/JCO.18.00685","volume":"37","author":"EA Stadtmauer","year":"2019","unstructured":"Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, et al. Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 Trial. J Clin Oncol. 2019;37:589\u201397.","journal-title":"J Clin Oncol"},{"key":"3682_CR17","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa032290","volume":"349","author":"M Attal","year":"2003","unstructured":"Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349:2495\u2013502.","journal-title":"N Engl J Med"},{"key":"3682_CR18","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/jnci\/djn439","volume":"101","author":"A Kumar","year":"2009","unstructured":"Kumar A, Kharfan-Dabaja MA, Glasmacher A, Djulbegovic B. Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst. 2009;101:100\u20136.","journal-title":"J Natl Cancer Inst"},{"key":"3682_CR19","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","volume":"30","author":"P Sonneveld","year":"2012","unstructured":"Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/GMMG-HD4 trial. J Clin Oncol. 2012;30:2946\u201355.","journal-title":"J Clin Oncol"},{"key":"3682_CR20","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","volume":"4","author":"NC Munshi","year":"2020","unstructured":"Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4:5988\u201399.","journal-title":"Blood Adv"},{"key":"3682_CR21","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1182\/blood.2022016782","volume":"141","author":"B Paiva","year":"2023","unstructured":"Paiva B, Manrique I, Dimopoulos MA, Gay F, Min CK, Zweegman S, et al. MRD dynamics during maintenance for improved prognostication of 1280 myeloma patients in TOURMALINE-MM3 and -MM4 trials. Blood. 2023;141:579\u201391.","journal-title":"Blood"},{"key":"3682_CR22","doi-asserted-by":"publisher","first-page":"e422","DOI":"10.1016\/S2352-3026(21)00130-7","volume":"8","author":"B Diamond","year":"2021","unstructured":"Diamond B, Korde N, Lesokhin AM, Smith EL, Shah U, Mailankody S, et al. Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. Lancet Haematol. 2021;8:e422\u201332.","journal-title":"Lancet Haematol"},{"key":"3682_CR23","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1200\/JCO.21.02228","volume":"40","author":"RM de Tute","year":"2022","unstructured":"de Tute RM, Pawlyn C, Cairns DA, Davies FE, Menzies T, Rawstron A, et al. Minimal residual disease after autologous stem-cell transplant for patients with myeloma: prognostic significance and the impact of lenalidomide maintenance and molecular risk. J Clin Oncol. 2022;40:2889\u2013900.","journal-title":"J Clin Oncol"},{"key":"3682_CR24","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1200\/JCO.21.01935","volume":"40","author":"LJ Costa","year":"2022","unstructured":"Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, et al. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J Clin Oncol. 2022;40:2901\u201312.","journal-title":"J Clin Oncol"},{"key":"3682_CR25","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13045-021-01135-w","volume":"14","author":"J Martinez-Lopez","year":"2021","unstructured":"Martinez-Lopez J, Alonso R, Wong SW, Rios R, Shah N, Ruiz-Heredia Y, et al. Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma. J Hematol Oncol. 2021;14:126.","journal-title":"J Hematol Oncol"},{"key":"3682_CR26","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","volume":"127","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127:2955\u201362.","journal-title":"Blood"},{"key":"3682_CR27","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u201346.","journal-title":"Lancet Oncol"},{"key":"3682_CR28","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s12185-019-02615-z","volume":"109","author":"H Takamatsu","year":"2019","unstructured":"Takamatsu H, Yoroidaka T, Fujisawa M, Kobori K, Hanawa M, Yamashita T, et al. Comparison of minimal residual disease detection in multiple myeloma by SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry. Int J Hematol. 2019;109:377\u201381.","journal-title":"Int J Hematol"},{"key":"3682_CR29","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"3682_CR30","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41409-022-01631-8","volume":"57","author":"D Karam","year":"2022","unstructured":"Karam D, Gertz M, Lacy M, Dispenzieri A, Hayman S, Dingli D, et al. Impact of maintenance therapy post autologous stem cell transplantation for multiple myeloma in early and delayed transplant. Bone Marrow Transplant. 2022;57:803\u20139.","journal-title":"Bone Marrow Transplant"},{"key":"3682_CR31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","volume":"20","author":"GH Jackson","year":"2019","unstructured":"Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C, et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20:57\u201373.","journal-title":"Lancet Oncol"},{"key":"3682_CR32","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1038\/s41375-020-0819-8","volume":"34","author":"H Goldschmidt","year":"2020","unstructured":"Goldschmidt H, Dimopoulos MA, Rajkumar SV, Weisel KC, Moreau P, Chng WJ, et al. Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma. Leukemia. 2020;34:3019\u201327.","journal-title":"Leukemia"},{"key":"3682_CR33","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1200\/JCO.21.01045","volume":"39","author":"P Sonneveld","year":"2021","unstructured":"Sonneveld P, Dimopoulos MA, Beksac M, van der Holt B, Aquino S, Ludwig H, et al. Consolidation and maintenance in newly diagnosed multiple myeloma. J Clin Oncol. 2021;39:3613\u201322.","journal-title":"J Clin Oncol"},{"key":"3682_CR34","doi-asserted-by":"publisher","first-page":"4647","DOI":"10.1182\/blood-2012-11-464503","volume":"121","author":"UH Mellqvist","year":"2013","unstructured":"Mellqvist UH, Gimsing P, Hjertner O, Lenhoff S, Laane E, Remes K, et al. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood. 2013;121:4647\u201354.","journal-title":"Blood"},{"key":"3682_CR35","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41408-018-0147-7","volume":"8","author":"MH Sidiqi","year":"2018","unstructured":"Sidiqi MH, Aljama MA, Bin Riaz I, Dispenzieri A, Muchtar E, Buadi FK. Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma. Blood Cancer J. 2018;8:106.","journal-title":"Blood Cancer J"},{"key":"3682_CR36","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/bjh.18249","volume":"198","author":"D B\u00f6ckle","year":"2022","unstructured":"B\u00f6ckle D, Tabares P, Zhou X, Schimanski S, Steinhardt MJ, Bittrich M, et al. Minimal residual disease and imaging-guided consolidation strategies in newly diagnosed and relapsed refractory multiple myeloma. Br J Haematol. 2022;198:515\u201322.","journal-title":"Br J Haematol"},{"key":"3682_CR37","first-page":"2163","volume":"4","author":"R Alonso","year":"2020","unstructured":"Alonso R, Cedena MT, Wong S, Shah N, R\u00edos-Tamayo R, Moraleda JM, et al. Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma. Blood Cancer J. 2020;4:2163\u201371.","journal-title":"Blood Cancer J"},{"key":"3682_CR38","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","volume":"22","author":"F Gay","year":"2021","unstructured":"Gay F, Musto P, Rota-Scalabrini D, Bertamini L, Belotti A, Galli M, et al. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncol. 2021;22:1705\u201320.","journal-title":"Lancet Oncol"},{"key":"3682_CR39","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.3324\/haematol.2021.280394","volume":"107","author":"C Touzeau","year":"2022","unstructured":"Touzeau C, Perrot A, Roussel M, Karlin L, Benboubker L, Jacquet C, et al. All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013\u201306 study. Haematologica. 2022;107:1693\u20137.","journal-title":"Haematologica"},{"key":"3682_CR40","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s11523-017-0524-3","volume":"12","author":"N Gupta","year":"2017","unstructured":"Gupta N, Yang H, Hanley MJ, Zhang S, Liu R, Kumar S. Dose and schedule selection of the oral proteasome inhibitor ixazomib in relapsed\/refractory multiple myeloma: clinical and model-based analyses. Target Oncol. 2017;12:643\u201354.","journal-title":"Target Oncol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-023-03682-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-023-03682-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-023-03682-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T12:26:46Z","timestamp":1704457606000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-023-03682-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,16]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["3682"],"URL":"https:\/\/doi.org\/10.1007\/s12185-023-03682-z","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,16]]},"assertion":[{"value":"25 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K. Suzuki received personal fees from Takeda Pharmaceutical Company, Janssen Pharmaceutical K.K., Sanofi, Bristol Myers Squibb, Ono Pharmaceutical Co., Ltd., outside the submitted work; H. Uryu received personal fees from Janssen Pharmaceutical K.K., Ono Pharmaceutical Co., Ltd., outside the submitted work; K. Nishiwaki reports personal fees from Pfizer and Alexion Pharmaceuticals Inc. and grants from Kyowa Kirin Co, Ltd, outside the submitted work; Dr. Yano reports grants from Kyowa Kirin, grants from Lilly Phrama, and grants from Otsuka Pharmaceutical, outside the submitted work;.the other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}